1. Is it Time to Update Societal Value Sets for Preference-Based Measures of Health?

   • A. Simon Pickard

   Editorial 14 January 2015 Pages: 191 - 192

2. Resource Modelling: The Missing Piece of the HTA Jigsaw?

   • Praveen Thokala
   • Simon Dixon
   • Beate Jahn

   Leading Article 20 November 2014 Pages: 193 - 203

   

3. A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis

   • Mickaël Hiligsmann
   • Silvia M. Evers
   • Annelies Boonen

   Systematic Review 07 November 2014 Pages: 205 - 224

   

4. Alteplase for the Treatment of Acute Ischaemic Stroke: A NICE Single Technology Appraisal; an Evidence Review Group Perspective

   • Michael Holmes
   • Sarah Davis
   • Emma Simpson

   Review Article 26 November 2014 Pages: 225 - 233

5. Is There an Economic Rationale for Cancer Drugs to Have a Separate Reimbursement Review Process for Resource Allocation Purposes?

   • Heather McDonald
   • Cathy Charles
   • Amiram Gafni

   Review Article 26 November 2014 Pages: 235 - 241

6. Costs of Health Resource Utilization Among HIV-Positive Individuals in British Columbia, Canada: Results From a Population-Level Study

   • Bohdan Nosyk
   • Viviane Lima
   • Julio S. G. Montaner

   Original Research Article 18 November 2014 Pages: 243 - 253

   

7. Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework

   • Mike Paulden
   • Tania Stafinski
   • Christopher McCabe

   Original Research Article Open access 21 November 2014 Pages: 255 - 269

   

8. Cost Effectiveness of Rivaroxaban for Stroke Prevention in German Patients with Atrial Fibrillation

   • Alexander Mensch
   • Stephanie Stock
   • Dirk Müller

   Original Research Article 18 November 2014 Pages: 271 - 283